Company
AsherBio
At Asher Biotherapeutics, we are pioneering a new approach with our cis-targeted immunotherapies.
Also known as Asher Bio, Asher Biotherapeutics, Inc.
- Status
- Operatingas of 2026-09-17
- Business model
- B2B
- Headquarters
- South San Francisco, CA, United States
- Legal name
- Asher Biotherapeutics, Inc.
- asherbio.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- X (opens in a new tab)
- Press page (opens in a new tab)
- Careers (opens in a new tab)
Claim, correct or request removal
Record updated 28 September 2026
About
Our immunotherapies selectively activate only the immune cell types that drive the desired therapeutic response. With this innovation, we address an inherent shortcoming of conventional immunotherapies, which indiscriminately act on multiple cell types, resulting in suboptimal efficacy and side effects.
Funding snapshot
- Total raised
- $218MSum of rounds, as of 2026-09-17Source (opens in a new tab)
- Latest round
- Series C, $55M2024-04-16
Funding rounds
- Series C
- $55M2024-04-16, Company stated
- Round, 2024
- $55M2024-04-03, SEC form D sold, 16 investors
- Series B
- $108M2021-09-01, Company stated
- Round, 2021
- $108M2021-08-20, SEC form D sold, 22 investors
- Series A
- $55M2021-03-23, Company stated
- Round, 2019
- $490K2019-08-19, SEC form D sold, 8 investors
Products
- Other
- etakafusp alfa (formerly known as AB248)
Loading relationship preview